By Mill Chart
Last update: May 5, 2025
Peter Lynch was known for finding hidden gems in the market before they became mainstream. Is UNITED THERAPEUTICS CORP (NASDAQ:UTHR) one of those under-the-radar stocks that fits his legendary strategy?
ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.
Overall UTHR gets a fundamental rating of 7 out of 10. We evaluated UTHR against 563 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making UTHR a very profitable company, without any liquidiy or solvency issues. UTHR scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes UTHR very considerable for value and quality investing!
Check the latest full fundamental report of UTHR for a complete fundamental analysis.
Every day, new Affordable Growth stocks can be found on ChartMill in our Peter Lynch screener.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
294.6
+0.75 (+0.26%)
Find more stocks in the Stock Screener
Let’s dive into UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation.